DexCom
DXCM
279 hedge funds and large institutions have $6.66B invested in DexCom in 2016 Q2 according to their latest regulatory filings, with 49 funds opening new positions, 111 increasing their positions, 88 reducing their positions, and 31 closing their positions.
58% more first-time investments, than exits
New positions opened: 49 | Existing positions closed: 31
26% more repeat investments, than reductions
Existing positions increased: 111 | Existing positions reduced: 88
24% more capital invested
Capital invested by funds: $5.37B → $6.66B (+$1.29B)
6% more funds holding
Funds holding: 264 → 279 (+15)
8% less call options, than puts
Call options by funds: $42.8M | Put options by funds: $46.7M
14% less funds holding in top 10
Funds holding in top 10: 7 → 6 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$207M |
| 2 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
+$111M |
| 3 |
WRF
Waddell & Reed Financial
Overland Park,
Kansas
|
+$70.9M |
| 4 |
Artisan Partners
Milwaukee,
Wisconsin
|
+$68.7M |
| 5 |
Wells Fargo
San Francisco,
California
|
+$64.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HM
HealthCor Management
New York
|
-$93.9M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$58.2M |
| 3 |
Viking Global Investors
Stamford,
Connecticut
|
-$33M |
| 4 |
Goldman Sachs
New York
|
-$32.7M |
| 5 |
Renaissance Technologies
New York
|
-$32.4M |
DXCM Hedge Fund Activity: Q2 2016 in Review
279 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in DexCom (DXCM) for Q2 2016, worth a combined $6.66B — up 24% from $5.37B a quarter earlier.
Buyers outnumbered sellers: 49 funds opened new DXCM positions and 31 closed out — a net gain of 18 holders — while 111 added to existing stakes and 88 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $207M. The largest seller was HealthCor Management, cutting an estimated $93.9M.
- 279 institutional investors held DexCom (DXCM) as of Q2 2016, up from 264 in Q1 2016.
- Funds reported $6.66B of DexCom stock for Q2 2016, up 24% quarter-over-quarter.
- 49 funds opened new DexCom positions in Q2 2016 and 31 closed out, a net change of +18 holders.
- The largest DexCom buyer in Q2 2016 was Fidelity Investments, an estimated $207M added.
- The largest DexCom seller in Q2 2016 was HealthCor Management, an estimated $93.9M sold.
Based on aggregated 13F filings for Q2 2016.